UTMD
UTAH MEDICAL PRODUCTS INCCompany Information
- Company Name
- UTAH MEDICAL PRODUCTS INC
- CIK
- CIK0000706698
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- UTMD: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3841
- SIC Description
- Surgical & Medical Instruments & Apparatus
- Ticker
- UTMD
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2023-05-18
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 1,350
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 2,287,035
- Shares outstanding
- 3,184,000
- Ownership
- 71.83%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- -1.43%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 88 | 87 | 86 | 84 | 82 | 83 | 83 | 88 | 89 | 94 | 93 | 88 | ||||||
| Accounts Receivable Net Current | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | ||||||
| Inventory Net | 9 | 9 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | ||||||
| Other Assets Current | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | ||||||
| Assets Current | 101 | 100 | 98 | 97 | 94 | 96 | 96 | 102 | 102 | 107 | 106 | 102 | ||||||
| Property Plant And Equipment Net | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 10 | ||||||
| Goodwill | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 13 | ||||||
| Finite Lived Intangible Assets Gross | 55 | 55 | 56 | 56 | 57 | 55 | 54 | 56 | 54 | 54 | 54 | 53 | ||||||
| Finite Lived Intangible Assets Accumulated Amortization | -55 | -55 | -55 | -55 | -55 | -52 | -51 | -52 | -50 | -50 | -49 | -47 | ||||||
| Intangible Assets Net Excluding Goodwill | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 4 | 4 | 4 | 5 | 6 | ||||||
| Assets | 125 | 124 | 123 | 122 | 121 | 123 | 123 | 130 | 130 | 135 | 135 | 131 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Tax Cuts And Jobs Act Of2017 Transition Tax For Accumulated Foreign Earnings Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 1 | - | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Accrued Liabilities Current | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 3 | 4 | 4 | 4 | ||||||
| Liabilities Current | 2 | 4 | 3 | 3 | 2 | 4 | 4 | 3 | 4 | 5 | 5 | 4 | ||||||
| Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Long Term Debt Noncurrent | - | - | - | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Operating Lease Liability | - | - | - | - | 0 | - | - | - | - | - | - | - | ||||||
| Long Term Debt And Capital Lease Obligations | 0 | 0 | 0 | - | - | 0 | 0 | - | - | - | 0 | - | ||||||
| Deferred Income Tax Liabilities Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Liabilities | 3 | 4 | 3 | 4 | 3 | 5 | 5 | 5 | 6 | 8 | 7 | 8 | ||||||
| Commitments And Contingencies | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accumulated Other Comprehensive Income Loss Before Tax1 | -10 | -10 | -9 | -10 | -9 | -11 | -12 | -10 | -11 | -11 | -11 | -12 | ||||||
| Additional Paid In Capital Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Retained Earnings Accumulated Deficit | 132 | 130 | 129 | 128 | 127 | 128 | 129 | 134 | 135 | 139 | 138 | 135 | ||||||
| Stockholders Equity | 122 | 120 | 119 | 118 | 118 | 117 | 117 | 124 | 124 | 128 | 128 | 124 | ||||||
| Liabilities And Stockholders Equity | 125 | 124 | 123 | 122 | 121 | 123 | 123 | 130 | 130 | 135 | 135 | 131 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Common Stock Shares Issued | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | ||||||
| Shares Outstanding | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialUTAH MEDICAL PRODUCTS INC (UTMD) — SEC Financial Statements & Analysis
UTAH MEDICAL PRODUCTS INC (UTMD) is a surgical & medical instruments & apparatus company, incorporated in UT. UTAH MEDICAL PRODUCTS INC trades on Nasdaq as: UTMD. UTAH MEDICAL PRODUCTS INC (UTMD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, UTAH MEDICAL PRODUCTS INC carries a market cap of $219.63M, a P/E ratio of 20.94x, a P/B ratio of 1.80x, a P/S ratio of 6.08x, an enterprise value of $132.30M, and an EV/EBITDA multiple of 11.91x. On profitability, it posts a gross margin of 57.90%, an operating margin of 28.43%, a net margin of 29.04%, a Return on Equity (ROE) of 8.75%, a Return on Assets (ROA) of 8.55%, and a Return on Invested Capital (ROIC) of 23.36%. Per share, it reports EPS of $3.29, diluted EPS of $3.29, free cash flow per share of $3.60, and a dividend per share of $1.24. Over the trailing year, it posted revenue growth of -7.00% year-over-year, net income growth of -16.46% year-over-year, and EPS growth of -14.84% year-over-year. On the balance sheet, it maintains a current ratio of 48.62x, a quick ratio of 44.27x, working capital of $98.57M, a debt-to-equity ratio of 0.02x, a debt ratio of 0.02, free cash flow of $11.45M (TTM), and net debt of $-87.33M. Figures sourced from SEC EDGAR.
- Market Cap
- $219.63M
- P/E TTM
- 20.94x
- EPS TTM
- $3.29
- P/B TTM
- 1.80x
- ROE TTM
- 8.75%
- ROA TTM
- 8.55%
- Debt To Equity
- 0.02x
- Free Cash Flow TTM
- $11.45M
- Net Revenue TTM Growth 1Y
- -7.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is UTAH MEDICAL PRODUCTS INC in?
UTAH MEDICAL PRODUCTS INC (UTMD) operates in the Surgical & Medical Instruments & Apparatus industry.
What exchange does UTMD trade on?
UTAH MEDICAL PRODUCTS INC (UTMD) trades on the Nasdaq.
Where is UTAH MEDICAL PRODUCTS INC incorporated?
UTAH MEDICAL PRODUCTS INC is incorporated in UT.
When was UTAH MEDICAL PRODUCTS INC (UTMD)'s most recent SEC filing?
UTAH MEDICAL PRODUCTS INC (UTMD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is UTMD's market cap?
UTAH MEDICAL PRODUCTS INC (UTMD) has a market capitalization of $219.63M as of 2026-06-30.
What is UTMD's P/E ratio?
UTAH MEDICAL PRODUCTS INC (UTMD)'s trailing twelve month P/E ratio is 20.94x as of 2026-06-30.
What is UTMD's EPS (earnings per share)?
UTAH MEDICAL PRODUCTS INC (UTMD)'s trailing twelve month EPS is $3.29 as of 2026-06-30.
What is UTMD's ROE (return on equity)?
UTAH MEDICAL PRODUCTS INC (UTMD)'s trailing twelve month Return on Equity (ROE) is 8.75% as of 2026-06-30.
What is UTMD's ROA (return on assets)?
UTAH MEDICAL PRODUCTS INC (UTMD)'s trailing twelve month Return on Assets (ROA) is 8.55% as of 2026-06-30.
What is UTMD's ROIC (return on invested capital)?
UTAH MEDICAL PRODUCTS INC (UTMD)'s trailing twelve month Return on Invested Capital (ROIC) is 23.36% as of 2026-06-30.
What is UTMD's EV/EBITDA?
UTAH MEDICAL PRODUCTS INC (UTMD)'s trailing twelve month EV/EBITDA is 11.91x as of 2026-06-30.